$ALAB

Astera Labs vs. BigBear.ai: Which Artificial Intelligence Stock Is a Better Buy in 2026?

The article compares AI-focused Astera Labs (ALAB) and BigBear.ai (BBAI). Astera Labs reported FY2025 revenue of $852.5M (+115.1%), net income of $219.1M, and FCF of $281.8M, with heavy customer concentration. BigBear.ai reported FY2025 revenue of $127.7M (-19.3%), net loss of $293.9M, and negative FCF of $42.5M, plus restatements and a class action.

Original reporting
Published Jul 29, 2026, 4:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 4:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astera Labs vs. BigBear.ai: Which Artificial Intelligence Stock Is a Better Buy in 2026? — source image
Decision brief

The 30-second read

$ALABBullishLow
01

Why it matters

It provides specific FY2025 financial outcomes for both companies and cites ALAB’s Q2 sales guidance range, but it does not present a clearly new, time-stamped corporate event (e.g., a fresh earnings release, contract award, or regulatory action) within the scraped text.

02

Market read

Traders may use the cited guidance and financial deterioration to frame relative risk, but the piece reads as a buy-vs-buy comparison rather than a fresh catalyst report.

03

What to watch

Neither company’s competitive dynamics, backlog/contract duration, or the status and magnitude of BBAI’s lawsuit/restatements are quantified in the text, which could materially change risk.

Relevance 4/10Novelty 3/10Timing: positioning for 2026 based on FY2025 results and ALAB Q2 sales guidance range

Background

The article contrasts Astera Labs’ rack-scale connectivity hardware with BigBear.ai’s AI decision intelligence software for government and related sectors.

Company-level read

Ticker impact

$ALABBullishMedium confidence
Context

Astera Labs is described as delivering record Q1 revenue of $308.4M and guiding Q2 sales to $355M-$365M, supporting a near-term demand narrative.

Expected impact

Mildly positive bias for ALAB versus peers if traders treat the guidance as credible and timely.

Evidence & confidence

The text provides specific revenue and guidance ranges, but it is a promotional comparison piece and does not clearly establish this as a newly released primary filing in the article itself.

$BBAIBearishMedium confidence
Context

BigBear.ai is described as having FY2025 revenue down 19.3% to $127.7M, with a net loss of $293.9M and negative free cash flow of -$42.5M.

Expected impact

Negative bias for BBAI, especially for traders focused on liquidity and contract-margin risk.

Evidence & confidence

The article includes concrete financial deterioration metrics, but it does not provide a clearly new catalyst (e.g., fresh filing, settlement, or contract award) beyond the stated FY figures.

Market effects

Highlights a split between AI infrastructure connectivity (hardware) and AI decision software for government (software), with different concentration and margin/cash profiles.

ALAB’s reliance on Taiwan fabrication and East Asia assembly/testing is flagged as a geopolitical supply-chain risk.

US government budget sensitivity is implied as a key demand driver for BBAI, linking defense spending cycles to AI software revenue.

Counterpoint

The comparison may over-weight narrative and already-known FY metrics; without confirmation of whether ALAB’s Q2 guidance is newly issued, the incremental trading edge is limited.

Key entities

  • Astera Labs

    AI data-center connectivity provider; article cites FY2025 profitability and Q2 sales guidance.

  • BigBear.ai

    AI decision intelligence provider for government; article cites FY2025 revenue decline, net loss, and negative free cash flow.

Related articles

$ALABMed

ALAB Benefits From PCIe Demand: Can It Stay Ahead of Its Competitors?

Astera Labs (ALAB) reported record Q2 2026 revenue of $392.4M, up 104% year over year, with PCIe 6 products at over 50% of revenue. The company said Scorpio X-Series will be its largest product family by Q3 2026. It expects Q3 revenue of $540M-$560M. The article also cites competition from Marvell (MRVL) and Credo (CRDO).

$ALABMedAI 8/10

Astera Labs (ALAB) Q2 2026 Earnings Call Transcript

Astera Labs (NASDAQ:ALAB) reported Q2 2026 revenue of $392.4M, up 27% sequentially and 104% year over year, with non-GAAP gross margin of 73.7% and non-GAAP diluted EPS of $0.80. Q3 guidance calls for revenue of $540M to $560M and EPS of $1.16 to $1.21, driven by the Scorpio X-Series ramp and PCIe 6.0 adoption.

$ALABHighAI 9/10

Alamar Biosciences Shares Rise 18% After Second-Quarter Revenue Jumps 82% Year-Over-Year

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.